Topical beta blockers are the most commonly used ocular hypotensive agents. Between 10% and 30% of patients may require additional therapy. however, 1-3 and the most fre quently used adjunct is topical pilocarpine. In 50% of cases control will be regained and this synergy of action may be due to differing modes of action of the two drugs.4') Pilo carpine requires a four times daily (q.i.d.) treatment sched ule to achieve a consistent effect,6.7 compared with the twice-daily (b.d.) schedule for topical beta blockers. Com pliance with glaucoma medication is adversely influenced by increasing complexity of treatment regime.x Twenty four hour diurnal studies by Maclure and Vogel9 suggest that the additive effect of pilocarpine on timolol is main- Other workers have shown that the hypotensive action of pilocarpine lasts for at least 12 hours when used as a fixed dose combination with 0.5% timolol.lO It appears that com bination with timolol produces synergy which extends the action of pilocarpine. Theoretically this should allow the use of a b.d. combined preparation of timolol and pilocar pine to achieve an additional hypotensive effect while maintaining compliance.
Topical beta blockers are the most commonly used ocular hypotensive agents. Between 10% and 30% of patients may require additional therapy. however, 1-3 and the most fre quently used adjunct is topical pilocarpine. In 50% of cases control will be regained and this synergy of action may be due to differing modes of action of the two drugs.4') Pilo carpine requires a four times daily (q.i.d.) treatment sched ule to achieve a consistent effect,6.7 compared with the twice-daily (b.d.) schedule for topical beta blockers. Com pliance with glaucoma medication is adversely influenced by increasing complexity of treatment regime. Other workers have shown that the hypotensive action of pilocarpine lasts for at least 12 hours when used as a fixed dose combination with 0.5% timolol.lO It appears that com bination with timolol produces synergy which extends the action of pilocarpine. Theoretically this should allow the use of a b.d. combined preparation of timolol and pilocar pine to achieve an additional hypotensive effect while maintaining compliance. This prospective study was undertaken to test the hypothesis that a combined preparation of timolol 0.5% and pilocarpine 2%, when used on a b.d. basis. produces satis factory control ofIOP in patients with open angle glaucoma over a 6-month trial period.
MATERIALS AND METHODS

Patients
Thirty patients with primary chronic open angle glaucoma (COAG) were recruited from the Glaucoma Clinic of St Paul's Eye Hospital . Liverpool.
Inclusion and Exclusion Criteria
The inclusion criteria were stable glaucoma over the pre ceding 12 months using both topical timolol (0.25% or 0.5%) b.d. and topical pilocarpine 2% q.i.d. such that lOP had been controlled at or below 21 mmHg with no evidence of continuing visual fi eld loss or optic disc deterioration.
The general exclusion criteria were asthma, chronic obstructive airways disease, cardiac failure or dysrhyth mia. The ocular exclusion criteria were acute ocular infec tion, previous uveitis, intraocular surgery, herpes simplex keratitis, corneal ulceration. contact lens wear, or any cor neal abnormality which might affect accurate applanation tonometry or drug penetration kinetics.
Pre-trial Assessment
After initial identification and recruitment of patients. all were assessed three times during the 3-week pre-trial period to determine baseline lOP values while using their accustomed medication. In this period patients were asked to use their usual treatment at 0800, 1200, 1600 and 2000 hours.
Examinations were then conducted at 1000 hours com prising visual acuity, pupil size, Goldmann three-minor gonioscopy, Goldmann applanation tonometry and fundus copy to assess the optic disc appearance. (The nature of the study made it impossible to perform masked measurements ofIOP but in all instances applanation was performed three times by one observer, without reference to the tonometry reading, which was recorded by an independent witness to eliminate observer bias.) The mean of the three readings was then calculated. On the first of the three visi ts Friedman mark II static visual fields were analysed. Heart rate and blood pressure were measured and any systemic or ocular symptoms noted. At the end of the 3-week period 2 patients were deemed not to fulfil the criteria for controlled glau coma and did not continue into the trial. Three patients failed to complete the full study period and are therefore not included.
Trial Schedule
The 25 patients who successfully completed the pre-trial assessment and follow-up were switched from their pre vious separate timolol and pilocarpine 2% to the combined b.d. timolol/pilocarpine preparation (TP2). These combi nation drops were reconstituted by the pharmacy staff of the Eye Hospital as described elsewhere 11 and were prescribed for instillation at 0800 and 2000 hours. Each bottle was used for 21 days before being discarded and a fresh one dispensed.
The patients were then examined at 1, 3 and 6 months with the same measurements as at the pre-trial visits; Fried man visual fields were tested on each occasion. In the event of IOP exceeding 21 mmHg at 1000 hours (2 hours after instillation of combined dosage preparation) or any deterioration in field or optic disc, patients using the TP2 preparation were withdrawn from the trial and returned to their previous medication and the Glaucoma Clinic for further management as judged clinically appropriate, and reassessed at I month following conversion back to original therapy.
For the purposes of statistical analysis, those patients who had both eyes treated had only one eye randomised into inclusion into the trial. 12 Patients withdrawn from the trial because of lack of control were excluded from further statistical analysis. At the end of the 6-month trial period all patients remain ing in the trial returned to their initial therapy and super vision and were assessed at I month following re conversion. All patients had access to the investigators during the period of the trial and replacement therapy from the pharmacy staff at St Paul's. Informed consent was obtained from each patient and the trial received Ethics Committee approval.
RESULTS
Of 30 patients initially recruited only 28 were deemed eligible for inclusion in the study after a 3-week initial study period. Three further patients did not complete all fol low-up visits and therefore a total of 25 patients (25 eyes) entered and completed the study period. All had lOPs at 1000 hours :oS 21 mmHg after instillation of usual timolol (0.25% or 0.5%) and pilocarpine (2%) at 0800 hours.
There were 13 men and 12 women with an age range of 54-8 1 years (mean 70.96 years). Control ofIOP was defined as lOP :oS 21 mmHg at 1000 hours. Mean lOPs in eyes prior to conversion, at 1, 3 and 6 months after conversion to com bination therapy, and at 1 month after reconversion to initial therapy are shown in Table I and graphically in Fig. 1 . Table  II and Fig. 2 demonstrate the percentage of eyes controlled by combination therapy at the same intervals.
Twenty-five eyes of 25 patients were included in the trial and deemed controlled initially. During the course of the trial only 17 eyes were controlled at 6 months. Of those 8 uncontrolled eyes, 6 regained control by conversion to orig inal therapy whilst 2 required control by argon laser trabeculoplasty.
Statistical Analysis
Statistical analysis was by a paired Student's t-test. were over short periods of 8 weeks maximum, though a recent study over 48 weeks drew similar conclusions. 17
In the fixed dose combinations the additive effect of pil ocarpine was said to last at least 12 hours when used in com bination with timolol. Other studies have reached similar conclusions.18,19 The 12 hour lOP control by application of TP 2 or TP4 was improved when compared with timolol 0.5%. In addition reduced mean diurnal lOP and reduced frequency of large pressure peaks were also recorded. 1 0 . 1 4
However, these findings are not surprising since the addi tion of another medication whether separately or as combi nation therapy would be expected to control lOP more effectively than a single medication. The real comparison is when combination treatment of TP 2 or TP 4 is compared with a regime of both timolol and pilocarpine separately. Indeed two studies suggested that fixed ratio combination treatment of TP 2 or TP4 (b.d.) was as effective in controlling lOP as timolol (b.d.) and pilocar pine (t.i.d.) given separately." 0 . 2 1 However, in these studies there was a loose regime of pilocarpine instillation, the studies were of 4 weeks duration and lOP was measured at 0800 hours prior to instillation of the next treatment dose.
One would expect that in view of all these findings9.lo, 2 o. 2 l combination therapy would be as effective as timolol b.d. and pilocarpine b.d. or t.i.d. given separately. Given that pil ocarpine's effect is prolonged to at least 12 hours with con comitant timololl 2 ,l5 then combination therapy should be as effective as timolol b.d. and pilocarpine q.i.d. given separately.
Our study was, therefore, specifically designed to mimic the clinical situation in which patients previously controlled on timolol b.d. and pilocarpine 2% q.i.d. in a pre-study period were converted to TP 2 (b.d.). The lOPs were measured at a specific time (1000 hours) after instillation of the morning dose (0800 hours) in both the pre-study and the study period. This was to reflect clinic management more closely.
We were disappointed to discover that in a long period of follow-up (6 months) only 17 of 25 eyes (68%) were con trolled. Of those 8 eyes uncontrolled on combination ther apy, 6 eyes became controlled on reversion to the original therapy, whilst 2 eyes did not.
The results of our study were at variance with the find ings of previous studies, in particular with those comparing timolol b.d. and pilocarpine t. 21 However, this was the same protocol for the pre-study period when patients were maintained and controlled on the previous therapy. Our study period was considerably longer (6 months) than that of most other similar studies of combination therapy (4-8 weeks) and perhaps this was significant. Progression of the disease process or tachyphylaxis may have been responsible for loss of controL though reversion to original therapy seemed to allow control in some patients and to be associated with a significant reduction in lOP in these patients. Non-compliance may have been a reason for failure, though miosis suggested patients were compliant and a b.d. regime would be more likely to encourage compliance.
The major variable lies in drug administration and kinetics. Timolol maleate has a pH 01'7. but at this pH pil ocarpine is unstable and pilocarpine is usually used in solu tions of pH 5.5.1 1" 1 In the combination used the pH was about 6.6. and though it converts more rapidly to pilocar pine acid and iso-pilocarpine acid it is probably stable for 3 weeks.22.23 However, this is a possible source of error since the pilocarpine in combination therapy may be more unstable22 than when used in acid solution as a single ther apy, leading to inactivation of the pilocarpine element of the fixed dose combination. This might lead to a relative inef ficacy of combination therapy compared with a separate treatment regime and explain our disappointing results. However, the higher pH encourages conversion to pilocar pine acid and iso-pilocarpine and the greater concentra tions of an ionised drug promote penetration of the cornea2'! and a greater hypotensive effect at pH 6.6 compared with lower pH values.2) Our trial can be criticised in that it was an open label study with no control group. However, the patients did act as 'their own controls' in that they had been studied in a pre study period before entering the trial. Indeed the aim of our study was to mimic the clinical situation as closely as poss ible with the combination treatment.
Although patient acceptibility was high, we feel that our experience with a fixed dose combination of timolol and pilocarpine (TP2) used b.d. does not allow us to recommend it for use in patients controlled on timolol b.d. and pilocar pine 2% q.i.d.
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